Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma
Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (AF)
NICE is unable to make a recommendation about the use in the NHS of tadalafil for treating symptoms associated with benign prostatic hyperplasia...
Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis (CF)
Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke (AIS)
Evidence-based recommendations on bevacizumab (Avastin) in combination with capecitabine for the first-line treatment of metastatic breast cancer
Evidence-based recommendations on aflibercept (Zaltrap) with FOLFIRI for metastatic colorectal cancer that has progressed after oxaliplatin
Evidence-based recommendations on total hip replacement and resurfacing arthroplasty for treating end-stage arthritis of the hip
Evidence-based recommendations on lapatinib (Tyverb) or trastuzumab (Herceptin) combined with an aromatase inhibitor for the first-line treatment of..
Evidence-based recommendations on fingolimod (Gilenya) for treating highly active relapsing–remitting multiple sclerosis (MS)
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in atrial fibrillation (AF)
Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia
Evidence-based recommendations on ocriplasmin (Jetrea) for treating vitreomacular traction in adults
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema after prior therapy
Evidence-based recommendations on peginterferon alfa and ribavirin (Pegasys) for treating chronic hepatitis C in children and young people
Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune (idiopathic) thrombocytopenic purpura (chronic ITP)
Evidence-based recommendations on botulinum toxin type A (Botox) for the prevention of headaches in adults with chronic migraine
Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults previously treated with docetaxel
Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for treating untreated chronic lymphocytic leukaemia
Evidence-based recommendations on aflibercept (Eylea) for treating diabetic macular oedema
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults
Evidence-based recommendations on the use of trastuzumab (Herceptin) for the treatment of advanced breast cancer
Evidence-based recommendations on dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block
Evidence-based recommendations on lenalidomide (Revlimid) for myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in people with alcohol dependence
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
Evidence-based recommendations on axitinib (Inlyta) for treating advanced renal cell carcinoma (RCC) (kidney cancer) when prior systemic treatment has failed
Evidence-based recommendations on infliximab (Remicade, Inflectra, Remsima) adalimumab (Humira) and golimumab (Simponi) for ulcerative colitis after..
Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention (PCI) for treating acute coronary syndrome (ACS)
Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure
Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-TK mutation-positive locally advanced or metastatic non-small-cell lung cancer..
NICE is unable to make a recommendation about the use in the NHS of canakinumab drug name (Ilaris) for systemic juvenile idiopathic arthritis..
Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis (RRMS/MS) in adults
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)
Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes
NICE is unable to make recommendations about regorafenib for metastatic colorectal cancer because no evidence submission was received from Bayer for the..
Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in people having a liver transplant
Evidence-based recommendations on vedolizumab (Entyvio) for treating moderately to severely active ulcerative colitis in adults
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing deep vein thrombosis (DVT) or pulmonary embolism
Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia
Evidence-based recommendations on cabazitaxel (Jevtana) for prostate cancer that has come back after it was treated with docetaxel
Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)
Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.
Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease
Evidence-based recommendations on ustekinumab (Stelara) for treating moderate to severe psoriasis in adults
Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours (cancer of stomach/digestive system)
Evidence-based recommendations on rituximab (MabThera) for the first-line treatment of chronic lymphocytic leukaemia (CLL)
Evidence-based recommendations on evacizumab (Avastin), soradenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for renal cell carcinoma